# 2026-15671: FDA erases 'gender' from rules to obey 'Biological Truth' executive order

2026-15671, Modification of Certain Terminology in Title 21; Reopening of the Comment Period, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-08-03, effective FDA is reopening the comment period on the proposed rule published on May 6, 2026 (91 FR 24380). Submit either electronic or written comments on the proposed rule by October 2, 2026. (as of 2026-08-10).

- Canonical: https://policyrisk.com/federal-register/2026-15671
- As of: 2026-08-10
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-15671
- Title: Modification of Certain Terminology in Title 21; Reopening of the Comment Period
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 48785
- Published: 2026-08-03
- Effective: FDA is reopening the comment period on the proposed rule published on May 6, 2026 (91 FR 24380). Submit either electronic or written comments on the proposed rule by October 2, 2026.
- Comments close: 2026-10-02
- Significant: no
- Touches household money: no
- Regulation identifier numbers: 0910-AJ26
- Last updated: 2026-08-10

## In one line

FDA erases 'gender' from rules to obey 'Biological Truth' executive order

## Summary

The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the proposed rule that appeared in the Federal Register of May 6, 2026, to modify certain terminology in Title 21 of the Code of Federal Regulations (CFR) to comply with Executive Order (E.O.) 14168, "Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government," issued on January 20, 2025. Specifically, this proposed rule, if finalized, will remove the term "gender" wherever it appears and either replace it with the term "sex," or delete reference to gender, as applicable, along with other editorial changes to improve readability. The Agency is taking this action to allow interested persons additional time to submit comments.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-15671 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/03/2026-15671/modification-of-certain-terminology-in-title-21-reopening-of-the-comment-period)
- [2026-15671 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-03/pdf/2026-15671.pdf)

## Related
- [Previous: 2026-15670, Roof Control Plan Approval Criteria](https://policyrisk.com/federal-register/2026-15670)
- [Next: 2026-15677, Petition for Reconsideration of Action in Rulemaking Proceeding](https://policyrisk.com/federal-register/2026-15677)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-15671 (as of 2026-08-10).